Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.

Mace TA, Ware MB, King SA, Loftus S, Farren MR, McMichael E, Scoville S, Geraghty C, Young G, Carson WE 3rd, Clinton SK, Lesinski GB.

Sci Rep. 2019 Mar 25;9(1):5068. doi: 10.1038/s41598-019-41687-z.

2.

Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.

Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA.

Pancreatology. 2019 Jan;19(1):80-87. doi: 10.1016/j.pan.2018.11.002. Epub 2018 Nov 10.

PMID:
30497874
3.

Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.

Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC.

J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):358-368. doi: 10.1002/jcsm.12251. Epub 2018 Jan 7.

4.

Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.

Belalcazar A, Shaib WL, Farren MR, Zhang C, Chen Z, Yang L, Lesinski GB, El-Rayes BF, Nagaraju GP.

Cancer. 2017 Dec 15;123(24):4924-4933. doi: 10.1002/cncr.30944. Epub 2017 Aug 25.

5.

Signaling pathways as therapeutic targets in biliary tract cancer.

Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB.

Expert Opin Ther Targets. 2017 May;21(5):485-498. doi: 10.1080/14728222.2017.1306055. Epub 2017 Mar 17. Review.

6.

Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z.

Cancer Res. 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1.

7.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

8.

Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB.

Mol Cancer Ther. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3.

9.

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS.

Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.

10.

Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.

Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB.

Clin Cancer Res. 2016 May 15;22(10):2565-74. doi: 10.1158/1078-0432.CCR-15-1732. Epub 2015 Dec 30.

11.

CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.

Rozanski CH, Utley A, Carlson LM, Farren MR, Murray M, Russell LM, Nair JR, Yang Z, Brady W, Garrett-Sinha LA, Schoenberger SP, Green JM, Boise LH, Lee KP.

J Immunol. 2015 May 15;194(10):4717-28. doi: 10.4049/jimmunol.1402260. Epub 2015 Apr 1.

12.

Stressful presentations: mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumor-bearing mice.

Kokolus KM, Spangler HM, Povinelli BJ, Farren MR, Lee KP, Repasky EA.

Front Immunol. 2014 Feb 10;5:23. doi: 10.3389/fimmu.2014.00023. eCollection 2014.

13.

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP.

Sci Signal. 2014 Feb 18;7(313):ra16. doi: 10.1126/scisignal.2004656.

14.

Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI.

J Clin Invest. 2013 Oct;123(10):4464-78. doi: 10.1172/JCI68189. Epub 2013 Sep 16.

15.

Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression.

Farren MR, Carlson LM, Lee KP.

Immunol Res. 2010 Mar;46(1-3):165-76. doi: 10.1007/s12026-009-8118-5. Review.

PMID:
19756409

Supplemental Content

Loading ...
Support Center